NeuroInitiative is a computational biology company. Our patented AI simulation platform has been identifying drug targets since 2014. Vincere Biosciences is the proof — a Parkinson's disease therapy entering Phase 1 clinical trials in 2026, discovered and developed from a target our platform prioritized.
Est. 2014 · A decade aheadIn 2014, before "AI drug discovery" was a category, we built a patented computational simulation engine to model neural molecular interactions and surface drug targets. We've been running it ever since. The result is a pipeline of programs — and one company about to dose its first human patient.
The most direct evidence that AI-driven target prioritization works — from a hypothesis in 2019 to a Phase 1 clinical program in 2026.
VB-23 is a best-in-class USP30 inhibitor — oral, brain-penetrant, non-covalent, with sub-10 nM potency and over 1000-fold selectivity. GLP toxicology studies are underway. IND-ready 2026. No disease-modifying therapy for Parkinson's currently exists.
Visit Vincere Biosciences →Vincere validated the platform. We're now exploring the next generation — pushing AI deeper into drug discovery, target identification, and scientific reasoning at the intersection of aging and disease.
Applying computational simulation to surface high-confidence drug targets across aging biology — beyond mitophagy, beyond neurodegeneration.
We have run lean and AI-first since 2014. From discovery to business development, AI is woven into how we operate — not as a tool layer, but as infrastructure.
USP30 inhibition shows efficacy across neurodegeneration, cardiorenal disease, and metabolic aging. We are mapping the full scope of the opportunity.
NeuroInitiative has operated for over a decade at the intersection of deep science and advanced computation. We are not a large organization. We are a deliberately lean one — two founders, a world-class scientific advisory network, and an expanding system of AI tools that multiply what a small team can discover, build, and accomplish. That model is becoming easier to understand today. We've been living it since 2014.